Welcome to our dedicated page for Bruker SEC filings (Ticker: BRKR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Bruker Corporation (Nasdaq: BRKR) SEC filings page provides access to the company’s U.S. regulatory disclosures, including current reports on Form 8-K, annual reports on Form 10-K, quarterly reports on Form 10-Q, and other key documents. These filings offer detailed information on Bruker’s financial condition, operating performance, capital structure, and material corporate events.
Bruker’s Form 8-K filings illustrate how the company reports significant developments such as quarterly and interim financial results, material modifications to security holder rights, and securities offerings. For example, Bruker has filed 8-Ks to furnish press releases with results of operations and financial condition for specific quarters, and to describe the issuance and terms of its 6.375% Mandatory Convertible Preferred Stock, Series A. That filing outlines the preferred stock’s dividend rate, liquidation preference, conversion mechanics into common stock, and related restrictions on dividends and share repurchases affecting junior and parity stock.
Through Forms 10-K and 10-Q, users can review segment information for Bruker Scientific Instruments and the Bruker Energy & Supercon Technologies (BEST) division, along with discussions of markets served, risk factors, and management’s analysis of results. These filings also describe how Bruker’s scientific instruments and diagnostic solutions support life science, applied, biopharma, industrial and cleantech research, and semiconductor metrology applications.
On this page, Stock Titan enhances Bruker’s raw SEC filings with AI-powered summaries that explain complex sections in plain language. Users can quickly understand the implications of Bruker’s 10-K and 10-Q reports, preferred stock terms, and other material events, while still having direct access to the original EDGAR documents. Filings related to insider transactions on Form 4 and proxy materials on Schedule 14A can also be monitored to track executive equity activity and governance matters over time.
BRUKER CORP executive Mark Munch reported an option exercise and share sale. On March 13, he exercised stock options for 2,000 shares of common stock at $22.19 per share, then sold 2,000 shares of common stock at $35.44 per share.
Following these transactions, he directly held 128,443 shares of common stock. The filing notes that the sale was carried out under a pre-arranged Rule 10b5-1 trading plan, indicating a planned, routine liquidity event rather than an opportunistic trade.
Mark R Munch reported sales of Common stock under Rule 144, including multiple transactions dated 01/05/2026, 01/12/2026, 01/15/2026, 02/13/2026, and a stock option exercise on 03/13/2026.
The filing lists individual dispositions of 33,843 shares on 01/05/2026 for $1,680,704, 7,000 shares on 01/12/2026 for $385,000, 2,000 shares on 01/15/2026 for $98,400, and 2,000 shares on 02/13/2026 for $73,880, plus a 2,000-share stock option exercise on 03/13/2026 paid in cash.
Bruker Corp Schedule 13G/A filing reports that Orbis Investment Management Ltd, Allan Gray Australia Pty Ltd and Orbis Investment Management (U.S.), L.P. together beneficially own 16,130,961 shares of common stock, representing 10.6% of the class. The filing breaks ownership by reporting person: Orbis Investment Management Ltd holds 15,197,866 shares; Orbis Investment Management (U.S.), L.P. holds 904,773; Allan Gray Australia Pty Ltd holds 28,322. The reporting persons state regulatory equivalence for non‑U.S. filers and disclaim group beneficial ownership.
Bruker Corporation files its annual report describing a global business built around four segments: BSI BioSpin, BSI CALID, BSI NANO, and BEST, focused on advanced scientific instruments and superconducting materials. The company serves life science, biopharma, materials, semiconductor, microbiology, diagnostics, and government markets with NMR, mass spectrometry, X-ray, microscopy, spatial biology, diagnostics, and superconducting technologies.
Bruker reports an aggregate market value of non‑affiliate stock of $4,251,097,535 as of June 30, 2025, with 152,219,250 common shares and 2,760,000 Series A mandatory convertible preferred shares outstanding as of February 20, 2026. Backlog was about $2,569.4 million at December 31, 2025, and the workforce totaled approximately 11,085 employees worldwide. Key risks highlighted include supply chain constraints, tariffs, reduced U.S. and Chinese research funding, geopolitical tensions, currency fluctuations, competition, and potential impairment of goodwill and other long‑lived assets.
Bruker Corporation announced board changes and a new dividend. Director Dr. Cynthia M. Friend will not stand for re-election as a Class II director when her term ends at the 2026 Annual Meeting, and her decision is stated as not due to any disagreement with the company. She will continue to serve until then.
On February 19, 2026, Jack Phillips stepped down as a Class III director and was immediately re-elected as a Class II director, with his board service deemed continuous from January 1, 2026, and his compensation and benefits unchanged. The board also declared a quarterly cash dividend of $0.05 per share on Bruker’s common stock, payable on April 7, 2026 to shareholders of record as of March 23, 2026.
FRANCIS LAURA reported acquisition or exercise transactions in this Form 4 filing.
Bruker Corporation director Laura Francis received an equity award of 4,520 shares of Common Stock in the form of restricted stock units on February 15, 2026. The RSUs will vest in a single installment on February 15, 2027. After this grant, she holds 9,018 shares directly.
Bruker Corp director Jack Phillips reported an equity award. On February 15, 2026, he acquired 4,520 shares of Common Stock through a grant classified as a “grant, award, or other acquisition.” The footnote explains this is represented by Restricted Stock Units that will vest in a single installment on February 15, 2027, when each unit will convert into one share of Common Stock. Following this award, his directly held position is reported as 4,520 shares.
BRUKER CORP director John A. Ornell received an equity grant of 4,520 shares of Common Stock in the form of restricted stock units. The award was reported at no cash purchase price and increased his directly held stake to 39,732 shares after the transaction.
The RSUs will vest in a single installment on February 15, 2027. On that vesting date, each restricted stock unit will automatically convert into one share of Bruker common stock, aligning the director’s compensation with future company performance over the vesting period.
BRUKER CORP director William A. Linton received an equity award of 4,520 restricted stock units (RSUs). The RSUs were granted at no cash cost and relate to the company’s common stock. After this grant, he directly holds 63,243 shares of common stock.
The footnote explains that these RSUs will vest in a single installment on February 15, 2027, and each RSU will automatically convert into one share of Bruker common stock at that time, aligning the director’s compensation more closely with future shareholder value.
Bruker Corp director Adelene Q. Perkins received an equity award of 4,520 restricted stock units (RSUs) of Common Stock on February 15, 2026. The RSUs will vest in a single installment on February 15, 2027, and each unit will convert into one share of Common Stock at vesting. After this grant, Perkins beneficially owns 29,144 shares of Common Stock directly.